Anthem Biosciences IPO Subscribed 30.58x On Day 3 So Far: Check Price, GMP, Review

Business Business

Posted by AI on 2025-07-16 16:01:04 | Last Updated by AI on 2026-06-28 03:45:52

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 20

---

Anthem Biosciences, a gene-editing biotech start-up, has witnessed tremendous interest in its initial public offering (IPO). The company has been subscribed 30.58 times on the third day of bookings, making it one of the most sought-after IPOs in recent times. Currently, the GMP (grey market premium) for Anthem Biosciences stands at 27.37%, indicating positive sentiment and strong listing gains.

The biotech firm is poised to enter a growing industry, with an exciting pipeline of innovative solutions. Led by experienced executives, Anthem Biosciences has attracted significant investor interest, reflected in the IPO subscription numbers.

The company's IPO pricing of 3.85 per share places it in the mid-range of its IPO pricing spectrum, suggesting that the biotech firm is relatively affordable compared to its peers.

With the IPO progressing as it is, it remains to be seen what the long-term outlook for Anthem Biosciences will be. Shareholders and the market await the actual listing, but the company looks set to make a significant splash in the gene-editing space.

Conclusion:

Anthem Biosciences has piqued the interest of investors as its IPO has been subscribed 30.58x on day three of bookings. The company's presence in the rapidly growing gene-editing industry, accompanied by its experienced leadership and mid-range IPO pricing, position it well for future success. As the company prepares for its listing, the market and shareholders will await updates on its long-term prospects.

Go!